高血压是持续血压过高的疾病,会引起 中风、心脏病、血管瘤、肾衰竭等疾病,高血压是一种以动脉压升高为特征,可伴有心脏、血管、脑和肾脏等器官功能性或器质性改变的全身性疾病。DHET、HETE类代谢物可作为检测高血压疾病的代表标志物,发挥着重要的作用。
12-HETE,ELISA的特异性是用真实的12-HETE和脂肪酸进行研究的,根据其结构,这些脂肪酸可能与12-HETE竞争结合对抗12-HETE的抗体。Anti-12 -HETE仅与15-HETE和13-HODE发生轻微交叉反应。这种代谢物在人类高血压中的作用非常之高。
14,15- DHET是可溶性环氧化物水解酶(sEH)介导的EETs代谢的代表性代谢物,由细胞色素P450 (CYPs) 2C和2J的花生四烯酸环氧合酶活性产生。使用14,15- DHET ELISA,发现14,15- DHET水平与高血压、脑损伤和中风呈正相关,EET水平与癌细胞转移表型和胰岛素抵抗呈正相关。
高血压是由于花生四烯酸(AA)ω-羟化酶(20-HETE合成)活性的细胞色素P450s CYP4A, CYP4F和CYP1B1的增加而确定的。因此,20-HETE已成为高血压和中风的生物标志物和治疗靶点。该ELISA试剂盒适用于最多24个生物样本(三份)中20-HETE的测定。
【 爆款 高血压相关产品】
货号 | 名称 | 规格 | 库存 |
DRD-DH1 | 14,15-DHET Hypertension ELISA | 1Kit | 现货 |
DRD-DH2 | 14,15-EET/DHET Hypertension ELISA | 1Kit | 现货 |
DRD-12H1 | 12-HETE Hypertension ELISA | 1Kit | 现货 |
DRD-15H1 | 15-HETE Hypertension ELISA | 1Kit | 现货 |
DRD-20H1 | 20-HETE Hypertension ELISA | 1Kit | 现货 |
【引文赏析】
【DRD-DH1】
Luo, J, Yao, J-F, Deng, X-F, Zheng, X-D, Jia, M, Wang, Y-Q, Huang, y and Zhu, J-H. 14,15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin avB3 and activating FAK/PI3K/AKT signaling. J. Exp Clin. Cancer Res. 37:23. 2018.
Akasaka T, Sueta D, Arima Y, Tabata N, Takasio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. CYP2C19 variants and epoxy eicosatrienoic acids in patients with microvascular angina. IJC Heart & Vasculature 15: 15-20 (2017).
【DRD-DH2】
Liu P, Zhang S, Gao J, Lin Y, Shi G, He W, Touyz RM, Yan L, Huang H. Downregulated serum 14,15- Epoxyeicosatrienoic acid is associated with abdominal aortic calcification in patients with primary aldosteronism. Hypertension 71: 592-598, 2018.
Akasaka T, Sueta D, Arima Y, Tabata N, Takasio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. CYP2C19 variants and epoxy eicosatrienoic acids in patients with microvascular angina. IJC Heart & Vasculature 15: 15-20 (2017).
【DRD-12H1】
González-Nú?ez, Daniel, Joan Claria, Francisca Rivera, Esteban Poch. Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 2001; 37: 334-338.
Szczeklik W, Sanak M, Mastalerz L, Soko?owska BM, Gielicz A, Soja J, Kumik J, Musia? J, Szczeklik A.12-hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg-Strauss syndrome. Clin Exp Allergy. 2012 Apr;42(4):513-22.
【DRD-15H1】
Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. Functional and pathological roles of the 12- and 15-lipoxygenases. Progress in Lipid Research (2011) 50, 115-131 and references therein.
Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, Honn KV. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev (2007) 26, 503–524 and references therein.
【DRD-20H1】
Bou-Fakhredin, R. et al. (2021) CYP450 mediates reactive oxygen species production in a mouse modl of B-thalassemia through an increase in 20-HETE activity. Int. J. Mol. Sci 22:110. PMID:?33498614 CYP4A and CYP4F-induced 20-HETE production mediates reactive oxygen species overgeneration in Hbbth3/+ mice.
Yu, J. et al. (2021) Cytochrome P450 CYP2E1 suppression ameliorates cerebal ischemia reperfusion injury. Antioxidants 10, 52. PMID:?33466250 20-HETE production increased 41% in CYP2E1 KO mice following ischemia reperfusion injury.
Detroit R&D完善的库存及供应体系以及稳定的纯化技术,保证产品均能现货供应和产品质量的稳定性。Detroit R&D研发公司已经建立了成功的销售记录,通过直接销售和24个分销商向美国和全球研究人员销售产品。18个美国国立卫生研究院(NIH)SBIR第一阶段和第二阶段(>1000万)奖项,以开发高血压诊断,线粒体DNA损伤测定,癌症微阵列,前列腺癌的糖基化生物标志物,糖基化蛋白在乳腺癌和循环核酸基肺癌中的生物标志物和8项已颁发专利和6项正在申请专利。
作为Detroit R&D在中国的区域代理,艾美捷科技有限公司将为中国客户提供最全面的Detroit R&D以及客户订制化服务。欢迎大家随时联系我们。
微信扫码在线客服